Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2019) 63 P1032 | DOI: 10.1530/endoabs.63.P1032

ECE2019 Poster Presentations Interdisciplinary Endocrinology 2 (37 abstracts)

Efficacy of growth hormone treatment in children with turner syndrome

Anzhalika Solntsava 1 , Nadzeya Peskavaya 2 & Natallia Akulevich 2


1State Medical University, Minsk, Belarus; 2The State Center for Medical Rehabilitation, Minsk, Belarus.


Objectives: To evaluate the efficacy of growth hormone (GH) treatment in children with Turner syndrome (TS) and to analyze the factors affecting the success of treatment.

Methods: Retrospective observational study was conducted for 62 patients with TS. 3 groups of patients were identified: group 1 with karyotype 45, X (n=32), group 2 with mosaic variant 45,X/46,XX (n=8), group 3 with structural anomalies of X chromosome (n=22). All patients were treated with GH at a dose of 0.33 mg/kg per day continuously for a year or more. A retrospective analysis of height (cm, SDS), growth velocity (cm/year), change in height SDS (ΔSDS), bone age before and during treatment was carried out. The results were processed using SPSS.22.

Results: TS was diagnosed in patients with characteristic phenotypic signs according to the results of karyotyping at the age of 6.7±5.07 (0.1–17.3) years. The chronological age at the start of GH treatment was 9.1±3.5 years (2.6–15.2). Most of the children had significant growth retardation (height SDS −2.87±0.93) and a low growth velocity (4.7±1.3 cm/year). Growth velocity increased with the use of GH in the first year of treatment. In group 1 the growth velocity was 7.2 [6.0; 9.5] cm/year versus 4.4 [3.48; 5.27] cm/year before treatment (P<0.001), in group 2 - 6.38 [6.1; 8.56] cm/year versus 3.95 [2.82; 5.42] cm/year (P=0.004) and in group 3–8.15 [7.02; 9.72] cm/year versus 5.05 [3.9; 6.1] cm/year (P<0.001). Height ΔSDS for 1 year of therapy was 0.49±0.3. The maximum change in height SDS were observed in girls with TS due to structural anomalies of the X chromosome (ΔSDS=0.55 [0.29; 0.72]), lower - in patients with monosomy X (ΔSDS=0.43 [0.23; 0.71]). To assess the effect of the age at initiation of therapy on the efficacy of treatment, groups of patients have been identified: up to 5 years, from 5 to 13 years, after 13 years. There was a small increase in bone age after GH therapy for 12 months in children under 5 years of age (0.5 years [0.5; 0.94]) versus 1.25 years [0.96; 2.0] in children older than 5 years (P=0.021) and 1.0 years [0.56;1,74] in children over 13 years old. This may worsen the growth prognosis with long-term GH treatment, given the lower baseline growth rates in TS children over the 5 years old.

Conclusions: For TS patients, GH treatment significantly increases growth rate. The age at initiation of therapy is an important prognostic factor.

Volume 63

21st European Congress of Endocrinology

Lyon, France
18 May 2019 - 21 May 2019

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.